Pulse Biosciences may offer up to $85,000,000 of common stock through Mizuho Securities USA LLC, with an assumed offering price of $54.21 per share. The company says the net proceeds would increase financial flexibility and provide additional Capital to support operations.

Key Highlights

  • Pulse Biosciences estimates up to 72,367,938 shares would be outstanding after the offering under its stated assumptions.
  • The prospectus lists 1,379,925 shares issued under the August 2026 program after June 30, 2026.
  • Pulse Biosciences says net proceeds would be used for greater financial flexibility and additional capital to support operations.

The prospectus uses $54.21 per share as an assumed offering price, which would correspond to the sale of 1,567,976 shares under its stated calculation. The company is the seller, and the offering would take place from time to time through Mizuho as sales agent. Pulse Biosciences (NASDAQ: PLSE) says it intends to use net proceeds to increase financial flexibility and obtain additional capital to support operations.

The company anticipates completing those sales before beginning transactions under the new sales agreement.

Assumed Price And Share Count

The stated post-offering share calculation reaches up to 72,367,938 shares, assuming the sale of 1,567,976 shares at $54.21 per share. The calculation starts with 70,799,962 shares outstanding as of June 30, 2026, while the actual number issued under the ATM will vary with sales prices. It also excludes 150,224 shares underlying warrants exercisable at $11.00 per share and 550,000 shares tied to outstanding restricted stock units. The prospectus also lists 388,949 shares issued through the February 2026 ATM after June 30, 2026, and 1,379,925 shares issued under the August 2026 program after that date. Up to approximately $6.2 million remained available under the August program as of the prospectus supplement date.

Proceeds For Operations

Pulse Biosciences identifies two principal uses for the net proceeds: greater financial flexibility and additional capital to support operations. The company also says the net proceeds, if any, would be used together with its existing resources.

Mizuho Sales Arrangement

Mizuho Securities USA LLC will act as the sales agent under the September 15, 2026, sales agreement. The common stock may be sold through an at-the-market offering from time to time. The Nasdaq Capital Market symbol is PLSE. The offering’s stated share count remains an estimate because the number issued depends on the sales price under the program.